Status:
RECRUITING
The Pathogenesis and Prognostic Factors of Lymphoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Lymphoma
Hodgkin Lymphoma
Eligibility:
All Genders
Brief Summary
The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.
Detailed Description
Lymphoma is a highly common malignant tumor in Asia. This study aims to observe and describe the clinical and genetic charateristics of Chinese lymphoma patients, and to explore the relationship betwe...
Eligibility Criteria
Inclusion
- Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027.
- Patients with complete diagnostic, treatment and follow-up records.
- Fully comprehension and signature of the informed consent form (ICF) for participation.
Exclusion
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period.
- Severe mental illness.
- Patients deemed unsuitable for inclusion by the investigator.
Key Trial Info
Start Date :
June 5 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT06203652
Start Date
June 5 2023
End Date
December 31 2028
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital，Fudan University
Shanghai, Shanghai Municipality, China, 200032